Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review
In a systematic review, Reuben Granich and colleagues assess the quality and comparability of publicly available data on national HIV care continua and progress towards the 90-90-90 targets.
Published in the journal:
. PLoS Med 14(4): e32767. doi:10.1371/journal.pmed.1002253
Category: Research Article
In a systematic review, Reuben Granich and colleagues assess the quality and comparability of publicly available data on national HIV care continua and progress towards the 90-90-90 targets.
In 2003, the World Health Organization (WHO) “3 by 5” initiative called for providing 3 million people living with HIV in low- and middle-income countries with antiretroviral treatment (ART) by the end of 2005 . Despite considerable skepticism regarding the advisability and feasibility of expanding access to ART, by June 2016 around 18.2 million, or 49% of people living with HIV, were taking ART . Efforts to expand access to treatment are supported by scientific evidence that treatment prevents illness and death, reduces human immunodeficiency virus (HIV) transmission, and can decrease health care costs [3–6]. Ensuring access to care and successful viral suppression is a challenge. Although hundreds of millions of HIV tests have been performed, one of the most important barriers to earlier ART and viral suppression is limited HIV diagnosis among people living with HIV, of whom only 60% had been diagnosed as of 2015 . Initiation of ART has primarily relied on CD4 cell count measurement, with access to the more useful viral load monitoring increasing only recently. The importance of accelerating access to diagnosis, treatment, and viral suppression as significant elements in ending the epidemic prompted the Joint UN Program on HIV/AIDS (UNAIDS) to release the HIV 90-90-90 target . The target specifies that by 2020, 90% of individuals living with HIV will be diagnosed and know their HIV status, 90% of people with diagnosed HIV infection will receive sustained ART, and 90% of those on ART will be virally suppressed . The target has been set as a minimum, with 95-95-95 by 2030 being envisioned as the target after 2020.
The establishment of the 90-90-90 target has placed increased emphasis on accurate monitoring and evaluation of the national continua of care from HIV diagnosis to viral suppression [9–15]. The importance of a standardized monitoring and evaluation framework was reflected in the 2001 UN General Assembly Special Session on HIV/AIDS that called for 13 core national-level indicators for monitoring progress . In 2003, the US President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund Against AIDS, Tuberculosis and Malaria (GFATM) resulted in an increase in resources for the global HIV response [17–19]. Efforts to improve both accountability and impact prompted the allocation of hundreds of millions of dollars for monitoring and evaluation of the HIV response. However, despite the commitment by stakeholders to a standard country-level monitoring and evaluation system , there has been an unprecedented increase in the number, type, complexity, and costliness of data collection systems, in part due to the expansion of individual site-level systems for clinical and program management. Reflecting the complex HIV response, these data are diverse, gathered from a variety of stakeholders on a large number of interventions and outcomes for a variety of purposes. The multiplicity of monitoring and evaluation systems, inconsistent methodologies often within the same geographic area, and paucity of data in the public domain create significant challenges for understanding fundamental questions about the impact of the investment in addressing the HIV epidemic. Specifically, despite the significant investment of approximately 19 billion US dollars (USD) per annum in the global HIV response and successfully providing access to treatment for 18.2 million people by June 2016 , many countries still face significant challenges when determining their national HIV care continuum [9,13,14,17,21–23].
The 90-90-90 target focuses on improving the continuum of HIV care from diagnosis to viral suppression . By specifying the proportion of diagnosis, ART, and viral suppression as important pillars of the HIV response, the target explicitly highlights the importance of providing treatment for nearly everyone and implicitly requires monitoring systems to measure progress. The indicators provide an important political and programmatic accountability framework and also emphasize the importance of achieving viral suppression through the continuum of care for at least 73% of people living with HIV by 2020. While there is growing consensus around the 90-90-90 target, measuring progress requires the ability to determine a country-level continuum of care that includes the proportions of all people living with HIV who are diagnosed with HIV, on ART, and virally suppressed [8,9]. Information regarding continua of care is limited, and efforts to describe global, national, and local continua of care have often used nonstandardized approaches or neglected to describe how the estimates were determined [23,24]. Pulling together the information is complicated by barriers that include the lack of a national cohort approach and individual patient identifiers, anonymous and unlinked testing and treatment services, and delays and loss to follow-up due to providing treatment only for those who are severely immunocompromised. As a result of these and other challenges, accurate national care continua from sub-Saharan Africa, the region with the highest HIV burden, are often unavailable or of uncertain quality. Our study aimed to answer these critical questions regarding data availability, quality, and progress toward 90-90-90: (1) What data for a complete officially endorsed national continuum of care are available in the public domain? (2) Of the national-level continuum data that are available, what are the quality and comparability of the information presented? How close are we to using a standard definition for measuring the continuum? and (3) How close are we to achieving the UNAIDS 90-90-90 targets? Which targets are proving to be the most challenging? How close are we to being able to measure the “third 90” (viral suppression)?
We used standard methods to search the public domain for the latest complete or near-complete national care continua (Fig 1). We used the national continua and accompanying methods to evaluate progress towards achieving the 90-90-90 target. In October 2016, we searched PubMed, UNAIDS and WHO reports, national surveillance and program reports, PEPFAR 2016 Country Operational Plans, and conference presentations and/or abstracts for national HIV continua of care for the period 2010–2016. The Google-based search strategy included the keywords (HIV OR AIDS) AND (treatment) AND (cascade OR continuum of care OR care continuum OR continua OR spectrum of care OR 90-90-90 OR viral suppression) for data published in the public domain. Although the search terms were in English and most of the sources were in English, some of the UNAIDS and/or country reports were in French or Spanish. We also searched the following conferences: International AIDS Society (IAS) Conference on HIV Science of 2015 and 2016, the Conference on Retroviruses and Opportunistic Infections of 2015 and of 2016, and the IAPAC Treatment as Prevention and Pre-exposure Prophylaxis Evidence Summit. We also included the following online databases: http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2016countries/ and https://www.pepfar.gov/reports/guidance/250167.htm.
The search was designed to identify the most recent officially reported or sanctioned national continua of care available in the public domain. To explore open data principles, the search was designed to be replicable by most nonacademic researchers, including people living with HIV, community organizations, clinicians, and other people.
From the continua, we collected data on the following four key steps in the treatment cascade: (1) estimated number of people living with HIV; (2) estimated number of people living with HIV diagnosed as HIV positive; (3) estimated number of people living with HIV receiving ART; and (4) estimated number of people living with HIV with a suppressed or undetectable viral load [25,26]. We used the estimated number of people living with HIV as the denominator to calculate the indicators for the continua (e.g., number of people on ART/estimated number of people living with HIV) and the numerators to calculate the 90-90-90 target. We relied on the country report of viral suppression using its lowest quantifiable threshold criteria. If data on the estimated number of people living with HIV (PLHIV) were unavailable, we used UNAIDS estimates to complete the cascade. We reviewed progress towards achieving the UNAIDS 90-90-90 target, which translates into 90% of PLHIV diagnosed, 81% of PLHIV on ART, resulting in 73% of PLHIV with viral suppression.
For countries with continua with viral suppression estimates, we also reviewed and ranked the methods for determining the four key care indicators. We contacted the authors if the care continua did not include methods for determining the “HIV diagnosis,” “on ART,” and “viral suppression” indicators. Using available WHO and International Association of Providers for AIDS Care (IAPAC) guidelines as the standard [25,26], the individual indicators were graded as high-, medium-, or low-quality based on quality of data, methods, and national representativeness (S1 Table key). Medium- and high-quality indicator data are interpreted as “satisfactory” for understanding the care continuum and monitoring the response. The quality of the indicator data was applied to the care continua; they were accorded an overall grade based on the lowest indicator grade.
There are significant challenges involved in the collection of the data necessary to put together a national care continuum. Specifically, without a cohort approach and patient identifiers, it is very challenging to link individual HIV diagnosis with care and treatment outcomes as it is often done in a different location with distinct data collection systems. Additionally, most countries still do not offer immediate treatment, and HIV diagnosis may be separated from starting treatment by many months to years . Likewise, viral load testing is often unavailable for all patients, and laboratory data systems may have difficulty deduplicating multiple samples for the same patient. Although there are an increasing number of high-quality population-based surveys with biologic sampling, the majority of countries rely on antenatal clinic surveillance and complex modelling to derive incidence and prevalence estimates that require wide confidence intervals. Data on HIV diagnosis, on ART, and viral suppression collected directly from program service delivery were accorded the highest value as they are drawn from individuals living with HIV who are receiving services and reflect progress towards targets. Program service delivery data were also classified as the highest grade since they serve as direct feedback regarding program performance. Other data sources such as community-based surveys, select quality assurance efforts, and/or laboratory information are also valuable and may be used to triangulate on the service delivery data—if triangulation using surveillance data was described as part of the methodology, the indicator was upgraded accordingly. High-grade continuum used methodologies that included all of the following: (1) national and/or UNAIDS estimates for the overall denominator of persons living with HIV or similar estimates derived from nationally representative surveys and surveillance, (2) a cohort or national program service database that included everyone diagnosed with HIV, (3) a national cohort or program service database for those on ART, and (4) individual viral load data for everyone on ART or cohort/surveys representative of everyone on ART. A medium grade was given to continuum that used one or more of the following: (1) estimates based on subnational/subpopulation data for the overall denominator, (2) HIV diagnosis based on population-based surveillance estimates (i.e., not program data) and/or diagnoses in select subpopulations, (3) ART coverage estimates using subpopulation cohorts or population-based surveillance (i.e., not program data), and/or (4) viral load suppression measured from a subsample of those on ART or population-based surveillance surveys (i.e., not program data). The medium grade was attributed to methodologies that used a population-based surveillance study or system since they can provide an accurate estimate of steps in the care continuum including viral suppression but do not directly measure program service delivery. Additionally, most surveys rely on self-report for being on ART. A low grade was given to continuum with the following characteristics: (1) estimates from modeling studies, (2) diagnosis derived from data in a nonrepresentative selection of clinics and/or hospitals or the numerator was not calculated, (3) ART coverage based on a nonrepresentative selection of clinics and/or hospitals, and/or (4) viral load data from a nonrepresentative selection of clinics and/or hospitals. If the source of one indicator was unknown, the continuum was ranked according to the grade of the remaining three indicators. The quality of the continuum was labeled as “unknown” if sources of the three indicators—i.e., PLHIV diagnosed, on ART, and with viral suppression—were unknown. This article was cleared by both Centers for Disease Control and Prevention and IAPAC. All data used for the study are available in the public domain at www.HIV90-90-90watch.org.
The PubMed search located 1,482 studies, which yielded 34 reported national care continua or cascades for all PLHIV (Fig 1). The wider Internet search located 127 reported national care continua. In case of multiple continua for an individual country, we used the most recently reported care continua to reduce the eligible number of care continua from 161 to 97. Of the 97, we excluded 15 care continua that were from secondhand reports and/or reported as preliminary and unconfirmed national figures. Of the 82 remaining care continua, we abstracted data on the four indicators. For the three countries missing estimates of PLHIV, we completed this portion of the care continuum using UNAIDS estimates [28,29]. The 29 continua that did not have data to calculate viral load suppression among PLHIV were excluded from further analysis and quality assessment. National care continua from 53 countries with viral suppression estimates were analyzed in detail. Of these, 9 care continua did not include the methods for determining the HIV diagnosis, on ART, and viral suppression indicators. Of these, we contacted the authors and obtained the methods for 2 continua.
We found care continua from 82 countries in the public domain from 2010–2016, representing 33.8 million (92%) of the 2015 global estimate of PLHIV . Of the 82 countries, only Sweden has achieved the 90-90-90 target (Table 1). Data on PLHIV diagnosed were available for 51 of 82 countries, data for the on ART indicator for 80 of 82 countries, and data for viral suppression for 53 of 82 countries. National care continua from these 53 countries are analyzed below.
The 53 national care continua with viral suppression estimates represented 19.7 million (54%) of the 2015 global estimate of PLHIV . The continua included 13 from European countries, 15 from North and South America, 15 from Asia, 9 from Africa, and 1 from Australia (Table 2). Care continua with viral suppression estimates were available in the public domain for only nine countries in sub-Saharan Africa (Kenya, Malawi, Mauritius, Namibia, Rwanda, South Africa, Swaziland, Uganda, and Zimbabwe), representing 35% of the 2015 HIV burden.
Of the 53 countries, 4 (Denmark, Kazakhstan, Romania, and Sweden) achieved the first 90 target of 90% PLHIV diagnosed, one (Sweden) achieved the second 90 target of 81% on ART, and one (Sweden) achieved the third target of 73% viral suppression (Table 1 and Fig 2). The proportion of PLHIV diagnosed on ART was >90% in 5 countries, and viral suppression among PLHIV on ART tested for viral load was >90% in 14 countries (Table 1). Seven countries (Sweden, Cambodia, UK, Switzerland, Denmark, Rwanda, and Namibia) have reached or were within 12% and 10% of achieving the 90-90-90 target for on ART and for viral suppression, respectively (Fig 3). Of the 53 countries, the percentage of PLHIV diagnosed was between 70%–89% in 18 countries, ART coverage among PLHIV was between 60%–80% in 14 countries, and viral suppression was between 50%–72% in 14 countries (Fig 2). The 53 countries averaged 48% of PLHIV on ART (the denominator was the aggregate of PLHIV in 53 countries) and 40% for viral suppression (Table 2). The average was not calculated for PLHIV diagnosed since many countries were missing data on this indicator. When restricted to those with care continuum from 2014 onwards (39 countries), these numbers were 52% and 43%, respectively. The 9 sub-Saharan African countries averaged 54% of PLHIV on ART and 44% for viral suppression (the denominator was the aggregate of PLHIV in 9 countries).
Progress towards the 90-90-90 target varied by country (Figs 4 and 5). The proportion of PLHIV on ART was generally higher in countries with a higher proportion of PLHIV diagnosed (Fig 4). However, countries with higher proportions of PLHIV diagnosed had varying proportions of ART coverage (19%–86%). Some countries are close to achieving the second and third 90-90-90 target; however, there is a range of estimated viral suppression (Fig 5).
Of the 53 continua, 6 (2% of the global HIV burden) were high quality, using standard surveillance methods to derive an overall denominator and program data from national cohorts for PLHIV with an HIV diagnosis, on ART, and with viral suppression (S1 Table and S2 Table—source of information and grading of methods quality). There were 28 (15% HIV burden) of medium quality, using only estimates for number of people diagnosed and/or on ART and/or viral load suppression. Fourteen continua (36% burden) were of low quality, and 5 (<1% burden) were unable to be graded because of missing data.
Estimating national HIV continuum of care helps to guide the global and local HIV response, and our study found that many national HIV programs have published their continuum for everyone living with HIV [9,10,13,14,21–23]. Recognizing the importance of expanding treatment, international donors, including PEPFAR and GFATM, are supporting efforts to achieve the 90-90-90 target and care continua to improve accountability and ensure impact . Our findings suggest that the substantial investment in expanding access to HIV diagnosis and treatment has resulted in significant progress towards the 90-90-90 target. The review also highlights that despite this investment, there is a lack of complete data available in the public domain coupled with a nonstandardized approach to determining national continua. The missing data and lack of standardization makes it difficult to determine with confidence whether many countries are on track to achieve the 90-90-90 target. However, although some of the program care continua data may be unavailable or unclear, recent population-based studies suggest that HIV program performance may be better than reported and treatment expansion has had a significant impact on viral suppression and HIV incidence .
Progress toward the 90-90-90 target
Complete information regarding national care continuum is difficult to find in the public domain, and we found only 53 national continua representing 54% of global HIV burden with viral suppression estimates (some of these were missing estimates for PLHIV diagnosed). Despite having 70% of the global burden for HIV in 2015 and 47% of the reported low- and middle-income country investment in the HIV response in 2012 [28,32], only nine countries from sub-Saharan Africa had continua in the public domain with viral suppression estimates. This lack of comprehensive data may be partly explained by obsolete “test and wait” strategies based on previous WHO guidelines. These strategies often include a fragmented monitoring and evaluation system resulting from stand-alone testing services combined with referral and delayed treatment only when a patient is very ill or when s/he is determined by CD4 count measurement to be severely immunocompromised. An additional obstacle is that measuring viral load suppression is a relatively new component of the WHO recommended treatment strategy and access for people taking ART has been delayed in most settings. Alternatively, the missing care continua may not be in the public domain and may only be available to experts in Ministries of Health or other agencies. Perhaps the information is available using more sophisticated search methods or through reconstruction of continua using a variety of surrogate sources. Regardless, the lack of easily available continua information, including trends, for most countries suggests that there are still significant obstacles preventing both the estimation and publication of progress towards the 90-90-90 target.
The results indicate that Sweden has achieved the 90-90-90 target, and a number of countries are close to achieving the first and second 90 targets by 2020. However, global progress towards achieving the 90-90-90 target and epidemic control relies on achieving the third and most important target of 73% viral suppression. Of the 53 countries with data on PLHIV with viral suppression, only 15 (14% of 2015 global burden) reported >50% viral suppression levels. This has serious implications and may reflect lower proportions of people diagnosed with HIV and on ART or that many countries are still not benefiting from the science that clearly supports the health and prevention benefits from initiating ART irrespective of CD4 cell count [3–6,33–36]. In September 2015, WHO issued global guidelines reflecting the scientific data that indicate health and transmission benefits from initiating ART irrespective of CD4 cell count . However, although 33 countries have published guidelines recommending “test and treat,” the majority of the 53 countries in our review still follow the now obsolete CD4 <200, <350, or <500 cells/mm3 ART initiation criteria . The review suggests that countries that have published guidelines promoting earlier access to treatment including “test and treat” reported continua with an increased proportion of PLHIV who have a suppressed viral load.
Evaluating continua quality
For the 48 of the 53 continua with available methods, there was a considerable lack of standardization and quality. Of the available continua, only six countries with 2% of global HIV burden could be classified as having the highest-quality methods conforming to international recommendations [25,26]. Although grading continua includes a degree of subjective judgment, the task was complicated since many reported continua presented data without describing the methods used to estimate and calculate the individual indicators. Care continua for key populations, tuberculosis, or other groups are even less available in the public domain and often rely on lower-quality estimation methods. Our study illustrates that the lack of standardized and quality methods impacts interpretation of the results for all of the 90-90-90 targets across countries. Comparison of national progress requires caution and should be accompanied by a critical review of not only the reported results but also the methods used to derive the care continua indicators.
Challenges determining progress toward the 90-90-90 target
Estimating the First 90 was plagued by a lack of consistency in the methods used to determine HIV prevalence and the proportion of people diagnosed with HIV. Reliable prevalence estimates require population-based HIV surveillance or surveys  that include biologic data such as HIV diagnosis, viral load, presence of antiretrovirals (ARVs), and CD4 cell count combined with measurement of the impact of program implementation on outcomes such as HIV incidence and mortality. Although higher-quality estimates are feasible and have been made in some countries , most countries reviewed depended on modeled UNAIDS or national estimates using antenatal clinic or other subpopulation data or national consensus regarding the number of PLHIV. The recently completed population-based survey in three African countries illustrates the potential problems with modeling as it found incidence estimates in Zimbabwe that were around half of those reported by UNAIDS . For estimating the number of people diagnosed with HIV, most countries rely on aggregate data from HIV testing efforts, estimates of those in care, and/or periodic surveys with self-reporting of known status with varying success, timeliness, and confidence. Reporting on the proportion of people with an HIV diagnosis is often on the basis of the number of tests done and the number found positive, which, without identifiers, makes it difficult to determine the number of new individuals tested and the overall proportion of HIV cases detected. Additionally, since HIV testing is often carried out in both governmental and nongovernmental settings, it is often impossible to say with certainty whether those with a positive HIV test access treatment. Without individual identifiers or other means to count newly diagnosed individual persons, there is no way to ensure linkage to care or record deaths, and data therefore may include an unknown amount of retesting by persons previously diagnosed. The clear benefits of immediate treatment for the prevention of illness, death, and transmission highlight the importance of establishing a monitoring and evaluation system that is accountable for everyone who receives an HIV diagnosis so that they can access treatment and achieve viral suppression.
Reporting for the Second 90 was available for most countries included in the review that used national program service data to report the number and proportion of people on ART. However, most did not describe what criteria are used to define “receiving or on ART” or other efforts to insure data quality, including deduplication to avoid overcounting. The IAPAC Continuum of Care Guidelines recommend using a defined program measure such as at least one drug pickup during the measurement period . WHO guidance recommends that ART patients seen within 90 d of a last drug pickup appointment, and excluding those who are deceased, are considered to be receiving ART . While ensuring access to treatment is critical, it is also important to be able to monitor and evaluate long-term retention in care and viral suppression. However, given the challenges posed by adherence and retention and the variance in how it is defined, the number of people reported “receiving or on ART” may be an unreliable measure of the actual number of people who are actually virally suppressed. Directly measuring viral suppression for everyone on ART is the best means to determine whether a person is both receiving and taking ART.
Measuring the Third 90 is challenging for many countries, and only nine countries reported directly measuring viral load for all of the people on ART. The majority relied on the viral suppression rate among samples at the national laboratory to infer the proportion of people on ART who are suppressed. If most people on ART routinely receive a viral load test within the reporting period and duplication is avoided, then this can give a reasonable approximation of the proportion of people who are suppressed. However, in most settings viral load tests are not standard, may be duplicated, and are instead used in the context of assessing patients for failure due to drug resistance or nonadherence. In this situation, the level of suppression among everyone on ART may actually be much higher than reported for only those who are potentially failing; however, if many people who do not have viral load measures are no longer in care, then using unadjusted data from a national laboratory subsample of those in care could actually overestimate viral suppression. As viral load testing becomes increasingly available, it will be possible to move to direct measurement of viral suppression among people on ART, through routine viral load monitoring, as the best measure of program success.
Our study has some limitations. In an effort to indirectly measure accountability and progress, we purposefully relied on official national care continua in the public domain. Therefore, our exhaustive public domain search may have missed other continua that have been recently published or are available only to health authorities or researchers. Additional challenges for accurately reporting comprehensive national care continua include siloed data collection with separate testing and treatment services, obsolete “test and wait” treatment protocols, lack of individual patient identifiers, and inability or unwillingness to adopt a unified single national cohort approach. More accurate and higher-quality continua measurement could be obtained by removing duplicate and redundant data collection efforts along with the adoption of unique identifiers and a standardized unified national cohort approach applied across all HIV services to help ensure the linkage of individuals to successful ART and viral suppression results. The study represents a single point in time, many countries do not regularly update published information, and we relied on the latest published or presented information, sometimes as old as from 2010. Additionally, while most continua described their methodologies, the quality of data collection and other more detailed methodological issues may have been missed. The heterogeneity in country-specific methods for monitoring the continua of care creates complex issues when comparing progress towards targets across countries. Only a few countries could produce national cohorts and/or national program data that include HIV diagnosis through viral suppression. Most countries reported derived estimates of continua numerators, which may be prone to data errors and methodological flaws. Specifically, without patient identifiers and a cohort system, patient loss after diagnosis, duplication of patients in the system, and lack of individually linked viral load results may compromise the validity of some continua. Also, this study did not evaluate the availability of high-burden subnational or population-specific care continuums (e.g., key populations), which may more directly inform strategies for targeted program improvement and community incidence interruption .
Despite ongoing efforts and considerable investments to improve monitoring and evaluation, our review highlights the need for improved standardization across countries to accurately track progress towards epidemic control. Guidelines for measuring continuum indicators exist [25,26]. To ensure accountability and measure progress towards 90-90-90, and there needs to be a renewed commitment by national governments and international donors to use a standardized continuum methodology. Refocusing investment to support standardization of national HIV cascade monitoring and evaluation according to the IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents and the WHO Consolidated Strategic Information guidance may help to improve availability and quality of care continua [25,26]. As part of this effort, it will be important to clearly define and describe standard numerators and denominators so that “diagnosed HIV,” “receiving ART,” “on ART,” and “viral suppression” have the same meaning regardless of national setting. Additionally, continuum for patients with HIV-associated tuberculosis, pregnant women, youth, and key populations may also prove to be useful . While accurate program data are essential to monitor service delivery and progress, routine case-based surveillance can also be considered as a tool to monitor generalized HIV epidemics or infections in key populations as well as to promote linkage to care . Resources devoted to testing and treatment services, strategic information, health systems strengthening, and community support should be prioritized to focus on building standardized national cohorts with individual patient identifiers and the ability to easily produce accurate national and subnational care continua. Periodic population-based household-level surveys that include biologic sampling for HIV, viral load, CD4 cell counts, and ARV drug levels should also be included as a means to corroborate program data and monitor progress towards ending AIDS.
Our study suggests that there is also considerable room for innovation in reporting progress to 90-90-90 and epidemic control. Our search revealed that essential data are all too often “buried” in inflexible, increasingly obsolete PDF formats, segmented or too old to meaningfully inform decision making. There is considerable potential for cloud-based software platforms that can provide multiple data visualization options and near real-time reporting of progress towards the 90-90-90 target and other important outcomes. Near real-time national and subnational monitoring could greatly improve the capacity to evaluate program implementation and thus further improve service delivery. Internet-based reporting using open data principles while protecting confidentiality could provide open access for health experts and the community, with the potential benefit of improving transparency, accountability, and timeliness of reporting. Without a significant improvement in quality and availability of data, it will be very challenging to successfully match adequate resources with gaps in progress towards the 90-90-90 target.
Decisions regarding monitoring and evaluation methodologies have major strategic implications. While it is clear that many countries are progressing toward and will likely achieve 90-90-90, it will be important to use consistent and accurate methods to report on progress. Specifically, the lack of standardization and variable quality suggest that reports of national continua and progress towards 90-90-90 require careful scrutiny . The benefits of standardized and comparable continua include improved accountability and stewardship of the scarce international and national program resources directed towards 90-90-90 and epidemic control. Keeping the important issue of individual patient confidentiality in mind, a standardized continuum system based on a unique identifier and a national program cohort of everyone living with diagnosed HIV would be a major step towards ensuring that everyone living with HIV has access to HIV diagnosis and treatment. Publishing high-quality continua of care data in the public domain could improve efficiency, transparency, and accountability and is essential to focus scarce resources on achieving 90-90-90 and epidemic control.
1. United Nations News Centre. UN agencies launch programme to treat 3 million HIV-infected people by 2005. December 2003. http://www.un.org/apps/news/story.asp?NewsID=9023&Cr=hiv&Cr1=aids.
2. Joint UN Programme on HIV/AIDS (UNAIDS). Fact Sheet 2016. Geneva, Switzerland. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf
3. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. Jul 17 2009;23(11):1397–1404. doi: 10.1097/QAD.0b013e32832b7dca 19381076
4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. The New England journal of medicine. Aug 11 2011;365(6):493–505. doi: 10.1056/NEJMoa1105243 21767103
5. Group ISS, Lundgren JD, Babiker AG, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. The New England journal of medicine. Aug 27 2015;373(9):795–807. doi: 10.1056/NEJMoa1506816 26192873
6. Group TAS, Danel C, Moh R, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. The New England journal of medicine. Aug 27 2015;373(9):808–822. doi: 10.1056/NEJMoa1507198 26193126
7. Joint UN Programme on HIV/AIDS (UNAIDS). Prevention Gap Report. Geneva, Switzerland. July 2016. http://www.unaids.org/sites/default/files/media_asset/2016-prevention-gap-report_en.pdf.
8. Joint UN Programme on HIV/AIDS (UNAIDS). 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland 2014. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf.
9. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. Mar 15 2011;52(6):793–800.
10. Greenberg AE, Hader SL, Masur H, Young AT, Skillicorn J, Dieffenbach CW. Fighting HIV/AIDS in Washington, D.C. Health affairs. Nov-Dec 2009;28(6):1677–1687. doi: 10.1377/hlthaff.28.6.1677 19887408
11. Hull MW, Wu Z, Montaner JS. Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Current Opinion in HIV and AIDS. Nov 2012;7(6):579–586. doi: 10.1097/COH.0b013e3283590617 23076123
12. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. Oct 2013;57(8):1164–1171.
13. Raymond A, Hill A, Pozniak A. Large disparities in HIV treatment cascades between eight European and high-income countries—analysis of break points. Journal of the International AIDS Society. 2014;17(4 Suppl 3):19507.
14. Medland NA, McMahon JH, Chow EP, Elliott JH, Hoy JF, Fairley CK. The HIV care cascade: a systematic review of data sources, methodology and comparability. Journal of the International AIDS Society. 2015;18:20634. doi: 10.7448/IAS.18.1.20634 26626715
15. Gardner EM, Young B. The HIV care cascade through time. The Lancet. Infectious diseases. Jan 2014;14(1):5–6. doi: 10.1016/S1473-3099(13)70272-X 24076276
16. United Nations General Assembly. Declaration of Commitment on HIV/AIDS. New York, United States. 2001. http://www.unaids.org/sites/default/files/sub_landing/files/aidsdeclaration_en_0.pdf.
17. Joint UN Programme on HIV/AIDS (UNAIDS). How AIDS changed everything MDG 6: 15 years, 15 lessons of hope from AIDS response. Geneva, Switzerland 2015. http://www.unaids.org/en/resources/campaigns/HowAIDSchangedeverything.
18. U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). http://www.pepfar.gov/.
19. The Global Fund to Fight AIDS, Tuberculosis and Malaria. http://www.theglobalfund.org/en/.
20. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS by the numbers. Geneva, Switzerland. 2016. http://www.unaids.org/sites/default/files/media_asset/AIDS-by-the-numbers-2016_en.pdf.
21. Greenberg AE, Purcell DW, Gordon CM, Barasky RJ, del Rio C. Addressing the challenges of the HIV continuum of care in high-prevalence cities in the United States. Journal of acquired immune deficiency syndromes. May 1 2015;69 Suppl 1:S1–7.
22. Supervie V, Marty L, Lacombe JM, Dray-Spira R, Costagliola D, group F-ACs. Looking beyond the cascade of HIV care to end the AIDS epidemic: estimation of the time interval from HIV infection to viral suppression. Journal of acquired immune deficiency syndromes. Nov 1 2016;73(3):348–355. doi: 10.1097/QAI.0000000000001120 27351889
23. Pineirua A, Sierra-Madero J, Cahn P, et al. The HIV care continuum in Latin America: challenges and opportunities. The Lancet. Infectious diseases. Jul 2015;15(7):833–839. doi: 10.1016/S1473-3099(15)00108-5 26122456
24. Kelly SL, Wilson DP. HIV Cascade Monitoring and Simple Modeling Reveal Potential for Reductions in HIV Incidence. Journal of acquired immune deficiency syndromes. Jul 1 2015;69(3):257–263. doi: 10.1097/QAI.0000000000000655 25886932
25. World Health Organization (WHO). Consolidated Strategic Information Guidelines for HIV in the health sector. Geneva, Switzerland. May 2015. http://apps.who.int/iris/bitstream/10665/164716/1/9789241508759_eng.pdf?ua=1&ua=1.
26. International Association of Providers of AIDS Care (IAPAC) Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents. Journal of the International Association of Providers of AIDS Care. Nov 2 2015. http://journals.sagepub.com/doi/pdf/10.1177/2325957415613442
27. International Association of Providers of AIDS Care (IAPAC). Global HIV Policy Watch. Washington DC, United States 2015. http://www.hivpolicywatch.org/.
28. UNAIDS. AIDSinfo Online Database. Geneva, Switzerland, 2015. http://www.aidsinfoonline.org/devinfo/libraries/aspx/Home.aspx.
29. Joint UN Programme on HIV/AIDS (UNAIDS). HIV estimates with uncertanity bounds 1990–2011. http://www.unaids.org/en/resources/campaigns/20121120_globalreport2012/globalreport/.
30. PEPFAR. PEPFAR 3.0 Controlling the Epidemic: Delivering on the Promise of an AIDS-free Generation. United States, 2014. http://www.pepfar.gov/documents/organization/234744.pdf.
31. Science. Southern Africa’s AIDS epidemic takes nosedive. December 2016. http://www.sciencemag.org/news/2016/12/southern-africa-s-aids-epidemic-takes-nosedive.
32. UNAIDS. UNAIDS report on the global AIDS epidemic 2013. Geneva, Switzerland 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf (Accessed on: 10 July 2014).
33. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. Aug 5 2006;368(9534):531–536. doi: 10.1016/S0140-6736(06)69162-9 16890841
34. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. The New England journal of medicine. Mar 30 2000;342(13):921–929. doi: 10.1056/NEJM200003303421303 10738050
35. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. Journal of acquired immune deficiency syndromes. Mar 1 2002;29(3):275–283. 11873077
36. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. The Lancet. Infectious diseases. Apr 2014;14(4):281–290. doi: 10.1016/S1473-3099(13)70692-3 24602844
37. World Health Organization (WHO). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva, Switzerland. September 2015. http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/.
38. De Cock KM, Rutherford GW, Akhwale W. Kenya AIDS Indicator Survey 2012. Journal of acquired immune deficiency syndromes. May 1 2014;66 Suppl 1:S1–2.
39. Gupta S, Granich R. National HIV Care Continua for Key Populations: 2010 to 2016. Journal of the International Association of Providers of AIDS Care 1–8. January 2017 (online). doi: https://doi.org/10.1177/2325957416686195
40. Hladik W, Benech I, Bateganya M, Hakim AJ. The utility of population-based surveys to describe the continuum of HIV services for key and general populations. International journal of STD & AIDS. Jan 2016;27(1):5–12. doi: https://doi.org/10.1177/0956462415581728
Článek vyšel v časopise
2017 Číslo 4
- Příznivý vliv Armolipidu Plus na hladinu cholesterolu a zánětlivé parametry u pacientů s chronickým subklinickým zánětem
- Berberin: přírodní hypolipidemikum se slibnými výsledky
- Armolipid Plus – doplněk stravy s potvrzeným účinkem na dyslipidemii
- Nutraceutikum Armolipid Plus podle klinických důkazů zlepšuje lipidový profil − metaanalýza
- Červená fermentovaná rýže účinně snižuje hladinu LDL cholesterolu jako vhodná alternativa ke statinové terapii
Nejčtenější v tomto čísle
- Talking sensibly about depression
- A new cascade of HIV care for the era of “treat all”
- Implementation science: Relevance in the real world without sacrificing rigor
- Silk garments plus standard care compared with standard care for treating eczema in children: A randomised, controlled, observer-blind, pragmatic trial (CLOTHES Trial)
Zvyšte si kvalifikaci online z pohodlí domova